3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Prostatic Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Brain Neoplasms
9
Sarcoma
7
Glioma
6
Meningioma
5
Lung Neoplasms
5
Esophageal Neoplasms
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Rhabdomyosarcoma
3
Radiation Injuries
3
Glioblastoma
3
Chondrosarcoma
3
Uterine Cervical Neoplasms
2
Solid Tumor
2
Pituitary Neoplasms
2
Pinealoma
2
Osteosarcoma
2
Oligodendroglioma
2
Nerve Sheath Neoplasms
2
Nasopharyngeal Carcinoma
2
Liver Neoplasms
2
Hodgkin Disease
2
Head and Neck Neoplasms
2
Ependymoma
2
Craniopharyngioma
2
Chordoma
2
Cholangiocarcinoma
2
Interventions
tanezumab
1
siltuximab
1
erenumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Saline Solution
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Protons
1
Proton Therapy
1
Lapatinib
1
Hyperspectral Imaging
1
HDAC-42
1
Bevacizumab
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neurilemmoma
×
Proton Therapy
×
Clear all
NCT04278118
2026-02-17
HiPPI
Emory University
Phase NA
Recruiting
70 enrolled